Tom is Co-founder and Executive Chairman of Grey Wolf and brings over 25 years of experience in drug discovery development and commercialization to the team. Tom is also Executive Chairman of Orbit Discovery (Oxford), Co-Founder and CEO of Pathios Therapeutics (Oxford) and Co-Founder and CEO of Molecule 2 Medicine Limited, a UK based consulting firm assisting global clients with the discovery, development and commercialisation of new human therapeutics, including new company formation and associated activities. From 2006-2015, he was President and CEO of Spinifex Pharmaceuticals, a private VC backed US/Australian biotech company developing first in class treatments for chronic pain, devoid of central nervous system side-effects. Spinifex Pharmaceuticals was purchased by Novartis in July 2015 for approximately US$700 million. Previous positions include Vice President of Drug Development at Starpharma Holdings Limited (Australia). He holds BSc (Hons) and PhD degrees from Monash University, Australia and completed his postdoctoral training at The University of Oxford.